|
|
Article: Fosamax(R) Increased Bone Mass in Men at Risk for Osteoporosis Due to Chronic Glucocorticoid Use.
- Article from:
- PR Newswire
- Article date:
- November 10, 1998
CopyrightCOPYRIGHT 1998 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SAN DIEGO, Nov. 9 /PRNewswire/ -- New data presented today at the annual meeting of the American College of Rheumatology showed the investigational use of Fosamax(R) (alendronate sodium) in men stopped bone loss and increased bone mineral density (BMD) at the spine and hip, two common sites of osteoporotic fracture. The men in the study all were at risk of osteoporosis and future fracture due to chronic use of glucocorticoids (commonly referred to as corticosteroids, or steroids).
"Previous studies have shown Fosamax to be effective in treating and preventing osteoporosis in postmenopausal women. These new data are important because they looked at the ...